Differential predictive factors for cardiovascular events in patients with or without cancer history

Daisuke Sueta, MD, PhD\textsuperscript{a,b,*}, Noriaki Tabata, MD, PhD\textsuperscript{a,b}, Satoshi Ikeda, MD, PhD\textsuperscript{c}, Yuichi Saito, MD, PhD\textsuperscript{d}, Kazuyuki Ozaki, MD, PhD\textsuperscript{d}, Kenji Sakata, MD, PhD\textsuperscript{a}, Takeshi Matsumura, MD, PhD\textsuperscript{b,g}, Mutsumo Yamamot-ibusuki, MD, PhD\textsuperscript{a}, Yoji Murakami, MD, PhD\textsuperscript{b}, Takayuki Jodai, MD\textsuperscript{d}, Satoshi Fukushima, MD, PhD\textsuperscript{d}, Naoya Yoshida, MD, PhD\textsuperscript{f}, Tomomi Kamba, MD, PhD\textsuperscript{d}, Eiichi Araki, MD, PhD\textsuperscript{b,g}, Hirotaka Iwase, MD, PhD\textsuperscript{h}, Kazuhiko Fujii, MD, PhD\textsuperscript{i}, Hironobu Ihn, MD, PhD\textsuperscript{k}, Yoshio Kobayashi, MD, PhD\textsuperscript{d}, Tohru Minamino, MD, PhD\textsuperscript{a}, Masakazu Yamagishi, MD, PhD\textsuperscript{d}, Koji Maemura, MD, PhD\textsuperscript{c}, Hideo Baba, MD, PhD\textsuperscript{b,j}, Kunihiko Matsuji, MD, PhD, MPH\textsuperscript{n}, Kenichi Tsujita, MD, PhD\textsuperscript{b,b}

Abstract

Although attention has been paid to the relationship between malignant diseases and cardiovascular diseases, few data have been reported. Moreover, there have also been few reports in which the preventive factors were examined in patients with or without malignant disease histories requiring percutaneous coronary intervention (PCI).

This was a retrospective, single-center, observational study. A total of 1003 post-PCI patients were divided into a malignant group, with current or past malignant disease, and a nonmalignant group. The primary endpoint was a composite of cardiovascular death, nonfatal myocardial infarction, stroke, revascularization, and admission due to heart failure within 5 years of PCI. Kaplan–Meier analysis showed a significantly higher probability of the primary endpoint in the malignant group (P = .002). Multivariable Cox hazard analyses showed that in patients without a history of malignant disease, body mass index (BMI) and the presence of dyslipidemia were independent and significant negative predictors of the primary endpoint (BMI: hazard ratio [HR] 0.73, 95% confidence interval [CI] 0.53–0.99, P = .041; prevalence of dyslipidemia: HR 0.72, 95% CI 0.52–0.99, P = .048), and the presence of multivessel disease (MVD) and the prevalence of peripheral artery disease (PAD) were independent and significant positive predictors of the primary endpoint (prevalence of MVD: HR 1.68, 95% CI 1.18–2.40, P = .004; prevalence of PAD: HR 1.51, 95% CI 1.03–2.21, P = .034). In patients with histories of malignancy, no significant independent predictive factors were identified.

Patients undergoing PCI with malignancy had significantly higher rates of adverse cardiovascular events but might not have the conventional prognostic factors.

Editor: Jianbing Wang.

The study was registered at the University Hospital Medical Information Network (UMIN)-CTR (http://www.umin.ac.jp/ctr/).

Identifier: KUMA study (UMIN000028653).

Opt-out materials are available at the following website: http://www.kumadai-junnai.com/home/wp-content/uploads/akusei.pdf.

The Consortium of Six National Universities in Japan jointly conducted research at Nagasaki University, Chiba University, Kanazawa University, Niigata University, Okayama University and Kumamoto University.

This study was supported, in part, by a Grant-in-Aid for Scientific Research (#17K09089) from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

Supplemental Digital Content is available for this article.

*Department of Cardiovascular Medicine, Graduate School of Medical Sciences, \textsuperscript{b}Department of Cardiovascular Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, \textsuperscript{c}Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine, Chiba, \textsuperscript{d}Department of Cardiovascular Biology and Medicine, Niigata University Graduate School of Medical and Dental Sciences, Niigata, \textsuperscript{e}Department of Cardiovascular and Internal Medicine, Kanazawa University Graduate School of Medicine, Kanazawa, \textsuperscript{f}Department of Metabolic Medicine, Faculty of Life Sciences, \textsuperscript{g}Department of Respiratory Medicine, Graduate School of Medical Sciences, \textsuperscript{h}Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, \textsuperscript{i}Department of Gastroenterological Surgery, Graduate School of Medical Sciences, \textsuperscript{j}Division of Translational Research and Advanced Treatment Against Gastrointestinal Cancer, \textsuperscript{k}Community, Family, and General Medicine, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.

Correspondence: Daisuke Sueta, Department of Cardiovascular Medicine, Graduate School of Medical Sciences, Kumamoto University, 1-1-1, Honjo, Chuo-ku, Kumamoto 860-8556, Japan (e-mail: sueta-d@kumamoto-u.ac.jp).

Copyright © 2019 the Author(s). Published by Wolters Kluwer Health, Inc.

This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Sueta D, Tabata N, Ikeda S, Saito Y, Ozaki K, Sakata K, Matsumura T, Yamamoto-Ibusuki M, Murakami Y, Jodai T, Fukushima S, Yoshida N, Kamba T, Araki E, Iwase H, Fujii K, Ihn H, Kobayashi Y, Minamino T, Yamagishi M, Maemura K, Baba H, Matsui K, Tsujita K. Differential predictive factors for cardiovascular events in patients with or without cancer history. Medicine 2019;98:44(e17602).

Received: 13 March 2019 / Received in final form: 16 September 2019 / Accepted: 19 September 2019
http://dx.doi.org/10.1097/MD.0000000000017602
1. Introduction

The original concept of onco-cardiology was developed on the basis of cardiotoxicity associated with anticancer treatment,[1–3] however, recently, the number of cases in which atherosclerotic cardiovascular diseases coexist with malignant diseases has increased, and increasing attention is being paid to the relationship between malignant diseases and cardiovascular diseases, based on the long-term surveillance of cancer survivors.[4–6] Several studies have described a high risk of cardiovascular disease events in cancer survivors.[7–13] Similarly, a history of cardiovascular disease also confers a higher risk of cancer.[14–19] Thus, this relationship has been receiving attention as a new aspect of onco-cardiology,[20–22] and these concepts were comprehensively reviewed recently.[23,24] We have observed that many malignant diseases and atherosclerotic diseases coexist in university hospitals (Supplemental Material, http://links.lww.com/MD/D292) and have proposed that university hospitals may represent a microcosm of the future population.[25] However, to the best of our knowledge the risk of cardiac events in coronary artery disease (CAD) patients with malignancy has not been well elucidated.

Moreover, our previous study[25] on the cardiovascular events in patients with comorbid malignancies and CADs was limited by the 1-year follow-up period, and long-term follow-up is required. In the present study, we therefore, examined the long-term clinical outcomes of cancer patients undergoing percutaneous coronary intervention (PCI).

Accumulating longitudinal studies have suggested that obesity is an independent predictor of CAD,[26,27] whereas it was also reported that body mass index (BMI) was inversely correlated with mortality in CAD patients.[28–31] This led to the proposal of the concept called the “obesity paradox,”[32] and there not yet any definite conclusions.[32] We also examined whether various factors, including the “obesity paradox,” contributed to the presence or absence of malignant diseases.

2. Methods

This study was a retrospective, single-center, observational study. The study was registered at the University Hospital Medical Information Network Clinical Trial Registry (UMIN000028652). This research was a collaborative study by the Consortium of Six National Universities in Japan (Nagasaki University, Chiba University, Kanazawa University, Niigata University, Okayama University, and Kumamoto University).

2.1. Ethics statement

All procedures were conducted in accordance with the Declaration of Helsinki and its amendments. The study protocol was approved by the institutional review boards of each institution.

2.2. Definition of malignant diseases

A detailed description is available in the Supplemental Material, http://links.lww.com/MD/D292

2.3. Definition of atherosclerotic diseases

Atherosclerotic diseases were defined by any clinical evidence of diseases thought to be due to atherosclerosis (ie, ischemic heart disease, ischemic heart failure, peripheral artery disease [PAD], aortic valve stenosis [excluding congenital bicuspid valve], arteriosclerotic aneurysm, arterial dissection, noncardiac cerebral infarction, and nephrosclerosis).

2.4. Study design

We reviewed the medical records of patients with malignancies as those with medical histories of previous and current malignant diseases. The present study is a sub-analysis of our previous study.[25] This study included 2200 consecutive PCI patients treated at the Kumamoto University Hospital between January 2007 and March 2017. We excluded the following patients: 806 duplicate patients; 12 patients who succumbed to in-hospital death; 364 patients with bare-metal stents (BMSs), balloon angioplasty, aspiration, PCI failure, and excimer laser coronary angioplasty? and 15 patients who were identified as having a malignancy after PCI. The remaining 1003 drug-eluting stent (DES)-only PCI patients were enrolled (Fig. 1). Acute coronary occlusion, which was a problem in the balloon catheter-only era, has been overcome by the advent of the BMS. With the development of the DES, the incidence of in-stent restenosis, which was a problem associated with BMS use, was reduced by several percentage points.[25] Recently, we do not have many opportunities to deploy BMS, and we use DES even for patients with acute coronary syndrome. Moreover, the latest guidelines on myocardial revascularization recommend that DES be used instead of BMS for any PCI.[13] Hence, it was necessary to establish a unified study of DES. Therefore, in this study, we decided to examine the effect of composite cardiovascular events, including restenosis on malignant diseases in DES-only cases. We divided the enrolled patients into 2 groups according to the presence of malignant diseases: the malignancy group and the nonmalignancy group (Fig. 1). The detailed definition of malignancy is described above.

2.5. Clinical parameters

The clinical parameters were described previously.[32,25,34] In brief, baseline demographic data, cardiovascular risk factors, and medications on discharge after PCI were documented. Hypertension was defined as blood pressure > 140/90 mm Hg or taking antihypertensive medication. We defined diabetes mellitus (DM) as the presence of symptoms of diabetes and a casual plasma
glucose concentration $\geq 200$ mg/dL, a fasting plasma glucose concentration $\geq 126$ mg/dL, and a 2-hours plasma glucose concentration $\geq 200$ mg/dL on a 75-g oral glucose tolerance test, or taking medication for DM. Dyslipidemia was defined as low-density lipoprotein $\geq 140$ mg/dL ($\geq 3.63$ mmol/L), high-density lipoprotein $< 40$ mg/dL (1.04 mmol/L), or triglycerides $\geq 150$ mg/dL ($\geq 1.7$ mmol/L). Chronic kidney disease (CKD) was defined as an estimated glomerular filtration rate (eGFR) $< 60$ mL/min/1.73 m$^2$. Current smoking status was determined via an interview. Acute coronary syndrome was defined as either an acute myocardial infarction (MI) (ST-segment elevation MI or non-ST-segment elevation MI) or unstable angina pectoris. We used the latest universal definition of MI in this study. Patients with past or current intermittent claudication associated with an ankle-brachial index value of $< 0.9$ in either leg were categorized as having PAD. Patients with previous ischemic stroke or transient ischemic attack were defined as having previous stroke. We recorded coronary lesions as the number of diseased coronary vessels. We defined the stenosis of more than 75% per the report from the American Heart Association to be significant and indicative of the need for primary PCI.

2.6. Follow-up and clinical events

The observations were performed by investigators who were blind to the patients allocation in this study. The agreement regarding the assessment of outcomes was achieved with the attainment of consensus among multiple evaluators in cases where doubts arose regarding endpoint decisions.

After PCI, patients were followed-up prospectively at outpatient clinics for 5 years or until an endpoint occurred. The primary endpoint was a composite of cardiovascular death, nonfatal MI, stroke, revascularization (target lesion revascularization [TLR] or non-TLR-revascularization) and admission due to heart failure up to 5 years (the median follow-up period was 343 days). At the 5-year follow-up visit, we measured the total number of endpoint events and stopped the analysis. Cardiovascular events were ascertained by reviewing the medical records and were confirmed by direct contact with the patients, their families, or their physicians. Cardiovascular death was defined as death due to MI or congestive heart failure or as documented sudden cardiac death. We defined revascularization (TLR or non-TLR-revascularization) as clinically-driven revascularization; specifically, revascularization was confirmed when the follow-up coronary angiography revealed restenosis or lesion progression and findings such as the presence of chest pain or positive results for stress myocardial scintigraphy or fractional flow reserve. There were no differences in the enforcement rate of follow-up coronary angiography between the 2 groups. For patients who suffered more than 1 cardiovascular event, only the first event was counted.

2.7. Sample size calculation

Our previous study showed approximately 20% of patients had malignant diseases in our institute. Accordingly, we planned a study of independent cases and controls with 5 controls per case. Our pilot data indicated that the probability of exposure among controls was 0.2. If the true probability of exposure among cases was 0.3, we would need to study 169 case-patients and 845 control patients to be able to reject the null hypothesis that the exposure rates for cases and controls are equal with a probability (power) of 0.8. The type I error probability associated with this test of the null hypothesis is 0.05.

2.8. Statistical analysis

The Shapiro–Wilk test was used to assess the normal distribution of continuous data. Continuous variables with normal distributions are expressed as the means ± standard deviation, whereas those with skewed distributions are expressed as the median values with their interquartile ranges. Categorical data are
Statistical analyses were performed using SPSS version 25 (IBM). The clinical characteristics of the study participants at baseline stratified by malignancy status are presented in Table 1. Differences between groups were tested using a Fisher exact test or a Chi-squared test for categorical variables, as appropriate. Differences in continuous variables were analyzed with analysis of variance or the Mann–Whitney test. We used the Kaplan–Meier method to estimate the cardiovascular event probabilities at 1825 days and a log-rank test to compare the distributions of survival times among the groups. Cox proportional hazard models were used to calculate hazard ratios (HRs). Multivariable analyses were tested in a multivariable analysis (P<.05). A P-value <.05 was considered to denote statistical significance. Statistical analyses were performed using SPSS version 25 (IBM Inc, Armonk, NY).

3. Results

3.1. Study population, the prevalence of comorbidities among the study participants and malignant disease incidence

Among 1003 enrolled DES-only patients, 17.8% (n=179) of the patients (18.9% [n=133] of males and 15.3% [n=46] of females) had a past medical history of malignant disease. Data for 998 PCI patients were available for the analysis of subsequent adverse cardiovascular events (data for 5 patients were unavailable). The clinical characteristics of the study participants were described previously. In brief, compared with patients without malignancy, patients with malignancy were older (patients with malignancy averaged 73.09 years old, and patients without malignancy averaged 69.75 years old) and had lower prevalence rates of dyslipidemia, current tobacco use, and previous stroke. Concerning the coronary and PCI details, we found no significant differences in single, double, triple, and left main trunk lesions between the malignant and nonmalignant groups. In addition, there were no significant differences in the frequency of medication usage (statins; angiotensin-converting enzyme inhibitors or angiotensin receptor blockers; beta-blockers; and proton pump inhibitors) upon discharge between the groups. In both groups, aspirin was used in approximately 97% of the patients, and P2Y12 inhibitors were used in approximately 94%; statistically there were no significant differences between the groups. These results rejected the possibility of reduced use of dual antiplatelet therapy in patients with malignancy. The clinical characteristics stratified by the presence of the event in the study participants are shown in Table 1. There were no significant differences among the patient characteristics between the event-positive (n=54) and event-negative groups (n=123) for patients with malignant diseases. For patients without malignant diseases, patients who experienced an event had lower BMI values, abdominal circumferences, eGFRs and ratios of single vessel diseases. Patients who experienced an event had higher prevalences of Diabetes and CKD and previous PAD.

3.2. Primary endpoints at the follow-up

During the follow-up period (median, 343 days), 221 (22.1%) of the patients experienced an adverse cardiovascular event (30.5% of the patients in the malignancy group and 20.3% of the patients in the nonmalignancy group). Kaplan–Meier analysis demonstrated a significantly higher probability of adverse outcomes in patients with malignancies than in the patients without malignancies (P=.002; Fig. 2). Details of the cardiovascular events are shown in Table 2, which shows that we found significantly higher rates of cardiovascular death and revascularization in the patients with malignancies than in the patients without malignancies (P=.003 and P=.02, respectively).

| Table 1 | Clinical parameters of the study participants at baseline stratified by malignancy status. |
|---------|--------------------------------------------------------------------------------------------------|
|         | Patients with malignancy (n=177) | Patients without malignancy (n=821) |
| Event (+) (n=54) | Event (–) (n=123) | P | Event (+) (n=167) | Event (–) (n=654) | P |
| Male sex, n (%) | 41 (75.9) | 91 (74.0) | .85 | 111 (68.5) | 456 (69.7) | .45 |
| Age, yr | 72.2±9.0 | 73.5±8.4 | .34 | 70.1±9.2 | 69.7±10.8 | .63 |
| BMI, kg/m² | 23.4±3.3 | 23.4±3.1 | .97 | 23.2±3.4 | 24.0±3.5 | .012 |
| AC, cm | 89.0±7.7 | 87.5±11.3 | .44 | 86.6±10.2 | 88.4±9.3 | .040 |
| ACS, n (%) | 18 (33.3) | 31 (25.2) | .28 | 44 (26.3) | 222 (33.9) | .064 |
| Diabetes, n (%) | 23 (42.6) | 67 (54.5) | .19 | 100 (59.9) | 325 (49.7) | .019 |
| Hypertension, n (%) | 37 (68.5) | 100 (81.3) | .079 | 139 (83.2) | 520 (79.5) | .33 |
| Dyslipidemia, n (%) | 32 (59.3) | 82 (66.7) | .40 | 115 (68.3) | 488 (74.6) | .14 |
| Current smoker, n (%) | 1 (1.9) | 13 (10.6) | .067 | 27 (16.2) | 124 (19.0) | .44 |
| CKD, n (%) | 26 (51.9) | 62 (50.8) | 1.0 | 84 (50.3) | 270 (41.3) | .044 |
| eGFR, ml/min/1.73 m² | 51.5±28.2 | 55.2±23.8 | .38 | 54.2±24.6 | 61.1±22.0 | <.001 |
| Previous MI, n (%) | 11 (20.4) | 19 (15.4) | .51 | 30 (18.0) | 81 (12.4) | .075 |
| Previous stroke, n (%) | 5 (9.3) | 17 (13.8) | .47 | 36 (21.6) | 119 (18.2) | .32 |
| PAD, n (%) | 9 (16.7) | 26 (21.1) | .55 | 38 (22.8) | 83 (12.7) | .002 |
| Single vessel, n (%) | 16 (39.6) | 43 (35.0) | .60 | 42 (25.1) | 250 (38.3) | .002 |
| Total cholesterol, n (%) | 12 (22.2) | 10 (8.1) | .009 |
| Radiotherapy | 8 (6.5) | 8 (14.8) | .04 |

Values are expressed as the mean ± standard deviation or n (%).

AC = abdominal circumference, ACS = acute coronary syndrome, BMI = body mass index, CKD = chronic kidney disease, eGFR = estimated glomerular filtration rate, MI = myocardial infarction, PAD = peripheral arterial disease.
3.3. Cox proportional hazards analyses for the primary endpoint

We carried out univariable and multivariable Cox proportional hazards analyses for the primary endpoints (Table 3). Multivariable Cox proportional hazard analysis was conducted with the forced inclusion model including conventional risk factors and showed that malignancy was an independent predictor of the primary endpoint (HR, 1.49; 95% confidence interval [CI], 1.10–2.04; \( P = .011 \)) and that BMI (above median = 23.52 kg/m\(^2\)) and the prevalence of dyslipidemia were independent and significant negative predictors of the primary endpoint (BMI: HR 0.74, 95% CI 0.56–0.96, \( P = .025 \); prevalence of dyslipidemia: HR 0.75, 95% CI 0.56–1.00, \( P = .048 \)).

We next performed univariable and multivariable Cox proportional hazards analyses for the primary endpoint in the malignancy and nonmalignancy groups (Table 4). In patients without histories of malignancy, BMI (above median = 23.52 kg/m\(^2\)) and the prevalence of dyslipidemia were independent and significant negative predictors of the primary endpoint (BMI: HR 0.73, 95% CI 0.53–0.99, \( P = .041 \); prevalence of dyslipidemia: HR 0.72, 95% CI 0.52–0.99, \( P = .048 \)), while the prevalence of multi-vessel disease (MVD) and the prevalence of PAD were independent and significant positive predictors of the primary endpoint (prevalence of MVD: HR 1.68, 95% CI 1.18–2.40, \( P = .004 \); prevalence of PAD: HR 1.51, 95% CI 1.03–2.21, \( P = .034 \)). In patients with histories of malignancy, no significant independent factors were identified.

3.4. Effect of cancer treatment on cardiovascular events

It has been suggested that chemotherapy and radiotherapy used in cancer treatments sometimes induce cardiotoxicity and cause heart failure, which was the original concept behind onco-cardiology/cardio-oncology. In the present study, 22 and 16 of 177 cancer patients had histories of chemotherapy and radiotherapy, respectively. Of the 177 patients with prognostic data, there was a significant difference in the occurrence of cardiovascular events between the chemotherapy experienced and naïve groups (chemotherapy experienced: 12/22 [54.5%]; chemotherapy naïve: 42/155 [27.1%], \( P = .009 \)), while there was no significant difference in the occurrence of cardiovascular events between the radiotherapy experienced and naïve groups (radiotherapy experienced: 8/54 [14.8%]; radiotherapy naïve: 8/123 [6.5%], \( P = .091 \)).

4. Discussion

“Onco-cardiology” or “cardio-oncology” has been used in reference to cardiotoxicity during the treatment of malignant diseases.\(^{1,2}\) While the adverse effects associated with recent progress in chemotherapeutic cancer treatments are concerning,\(^{38,39}\) the relationship between malignant diseases and cardiovascular diseases has also attracted attention.\(^{6,21,22}\) However, the comorbidity of malignant diseases and cardiovascular diseases has never been investigated extensively; therefore, we conducted this multicenter collaborative surveillance. As shown in Supplemental Figure 1, http://links.lww.com/MD/D292, the statistically significant coexistence of malignant diseases and atherosclerotic diseases was observed only in
Table 3

Cox proportional hazards regression analyses for clinical outcome within 5-year follow-up.

| Variable                  | Univariable analysis | Multivariable analysis |
|---------------------------|----------------------|------------------------|
|                           | HR       | 95% CI          | P-value | HR       | 95% CI          | P-value |
| Malignancy                | 1.62     | 1.19–2.20       | .002    | 1.49     | 1.10–2.04       | .011    |
| Age                       | 1.20     | 0.93–1.57       | .168    |          |                |         |
| Male sex                  | 0.95     | 0.71–1.26       | .697    |          |                |         |
| AC (above median)         | 1.00     | 0.75–1.33       | .991    |          |                |         |
| BMI (above median)        | 0.71     | 0.55–0.93       | .013    | 0.74     | 0.56–0.96       | .025    |
| ACS                       | 0.93     | 0.69–1.24       | .611    |          |                |         |
| Single vessel             | 1.63     | 1.20–2.19       | .002    |          |                |         |
| Family history            | 1.17     | 0.88–1.56       | .278    |          |                |         |
| Hypertension              | 1.15     | 0.83–1.59       | .418    |          |                |         |
| Diabetes                  | 1.11     | 0.85–1.45       | .444    |          |                |         |
| Dyslipidemia              | 0.67     | 0.53–0.93       | .012    | 0.75     | 0.56–1.00       | .048    |
| Smoking                   | 0.68     | 0.46–1.01       | .055    |          |                |         |
| CKD                       | 1.39     | 1.07–1.81       | .014    | 1.24     | 0.94–1.63       | .124    |
| Previous MI               | 1.33     | 0.95–1.87       | .099    |          |                |         |
| Previous stroke           | 1.09     | 0.77–1.52       | .637    |          |                |         |
| Previous PAD              | 1.605    | 1.162–2.22      | .004    | 1.31     | 0.939–1.834     | .112    |

AC = abdominal circumference, ACS = acute coronary syndrome, BMI = body mass index, CI = confidence interval, CKD = chronic kidney disease, eGFR = estimated glomerular filtration rate, HR = hazard ratio, MI = myocardial infarction, PAD = peripheral artery disease.

clinical departments that deal with atherosclerotic diseases at university hospitals (Group C).

The prevalence of obesity has dramatically increased not only in developed countries but also in developing countries,[40] and it has become a social problem worldwide. Although the relationship between obesity and CAD has been deemed to be due to cardiovascular risk factors such as hypertension and DM related to obesity, it has been previously reported that obesity itself was an independent predictor of CAD in longitudinal cohort studies.[26,27] However, in 2002, Gruberg et al reported that BMI was inversely correlated with mortality in CAD patients; this phenomenon was different from general perception, and therefore it led to the proposal of the concept called the “obesity paradox.”[28] After that, similar reports[29–31] were forthcoming. It was thought that the residual confounding factors contribute to this relationship,[31,32] but the mechanism has not been elucidated. As shown in Table 2, it was suggested that the presence of malignant disease might contribute to the discrepancy, which was possibly one of residual confounding factor. Moreover, the occurrence rate of events varies depending on the presence or absence of malignancy as previously reported.[12] Conventional prognostic factors, such as renal function, MI history, and PAD history, have not been applied to the malignant disease group as BMI and abdominal circumference have. The reason conventional prognostic factors do not apply in the malignant disease group is not clear, but the following reasons

Table 4

Predictors of clinical outcomes using the Cox proportional hazard model for the malignancy and non-malignancy groups.

| Variables                  | Patients with malignancy (n = 177) | Patients without malignancy (n = 821) |
|---------------------------|------------------------------------|--------------------------------------|
|                           | Univariable analysis | Multivariable analysis | Univariable analysis | Multivariable analysis |
|                           | HR       | 95% CI          | P-value | HR       | 95% CI          | P-value | HR       | 95% CI          | P-value |
| Male sex                  | 1.20     | 0.64–2.25       | .57     | 0.68     | 0.64–1.21       | .42     |          |          |         |
| Age above median          | 1.01     | 0.58–1.76       | .98     | 1.17     | 0.86–1.59       | .32     | 1.81     | 1.24–2.62     | .027    |
| BMI above median          | 0.85     | 0.50–1.45       | .54     | 0.69     | 0.51–0.94       | .017    | 0.73     | 0.53–0.99     | .041    |
| AC above median           | 1.54     | 0.86–2.74       | .15     | 0.88     | 0.63–1.22       | .43     | 1.59     | 1.07–2.38     | .072    |
| Family history            | 1.55     | 0.85–2.81       | .15     | 1.14     | 0.83–1.58       | .43     | 1.76     | 1.19–2.64     | .031    |
| Hypertension              | 0.64     | 0.36–1.14       | .13     | 1.45     | 0.97–2.18       | .072    | 1.39     | 0.89–2.19     | .15     |
| Diabetes                  | 0.65     | 0.38–1.12       | .12     | 1.32     | 0.97–1.80       | .08     | 1.60     | 1.12–2.26     | .039    |
| ACS                       | 1.92     | 1.08–3.42       | .027    | 0.79     | 0.56–1.11       | .18     | 1.63     | 1.04–2.58     | .039    |
| MVD                       | 1.19     | 0.64–2.08       | .63     | 1.76     | 1.26–2.52       | .001    | 1.68     | 1.18–2.40     | .004    |
| Current smoking           | 0.19     | 0.026–1.35      | .007    | 0.81     | 0.53–1.22       | .31     | 1.43     | 1.05–1.93     | .022    |
| CKD                       | 1.20     | 0.70–2.04       | .52     | 1.43     | 1.05–1.93       | .022    | 1.24     | 0.91–1.70     | .18     |
| Previous MI               | 1.20     | 0.62–2.33       | .60     | 1.34     | 0.90–1.99       | .15     | 1.55     | 1.06–2.27     | .039    |
| Previous stroke           | 0.71     | 0.28–1.79       | .47     | 1.23     | 0.85–1.78       | .28     | 1.53     | 1.05–2.24     | .029    |
| PAD                       | 0.80     | 0.39–1.63       | .54     | 1.92     | 1.34–2.76       | <.001   | 1.53     | 1.05–2.24     | .029    |

AC = abdominal circumference, ACS = acute coronary syndrome, BMI = body mass index, CI = confidence interval, CKD = chronic kidney disease, eGFR = estimated glomerular filtration rate, HR = hazard ratio, MI = myocardial infarction, PAD = peripheral artery disease.
can be suggested. Because malignant diseases and atherosclerotic diseases share certain risk factors, it would be reasonable to expect malignant disease patients to have atherosclerotic diseases. Furthermore, malignant diseases and atherosclerosis lesions are both characterized by inflammation. We have already reported that the combination of malignancy and high-high-sensitivity C-reactive protein levels has been associated with significantly higher incidences of cardiovascular events. Thus, we speculate that local malignancies increase vascular wall inflammation by increasing the levels of various inflammatory cytokines and that this circulatory inflammation causes progressive arteriosclerosis. As shown in the present study, conventional prognostic factors such as renal dysfunction and PAD history do not apply to the malignant disease group as BMI and abdominal circumference do (Table 1). Hence, 1 possibility why conventional prognostic factors do not apply to the malignant disease group is that malignancy itself might be a residual risk factor for cardiovascular events. Recently, the concept of clonal hematopoesis of indeterminate potential was proposed for myeloid malignancies, and Libby and Ebert comprehensively reviewed its contribution to cardiovascular risks. Hence, we believe that the important mechanisms underlying this association are common risk factors, inflammation, and clonal factors.

The results obtained in the present study (Fig. 2) were primarily caused by revascularization (Table 2). In Japan, it is common to perform follow-up coronary angiographies 8 to 12 months after PCI, and the results of these procedures were considered in the present study. We have already reported the details of this mechanism. It is well known that radiotherapy, especially thoracic radiotherapy, promotes atherosclerosis. In this study, the possibility of a synergistic relationship between radiotherapy and revascularization was proposed.

5. Study limitations

The present study has several limitations. First, this study was a retrospective single-center observational study. Despite the relatively small number of patients involved, we included patients from a large catchment area and, thus, included a high number and a wide range of cancers among the patients studied, reflecting the broader incidences observed nationally and/or worldwide. In particular, there is a possibility that predictive factors were not identified in the malignancy group due to the small sample size and low statistical power. Second, the possibility that the clinical endpoints observed in this study were influenced by patient medications, the use of anticancer agents or thoracic irradiation cannot be ignored. Third, it is not clear whether patients with both malignant diseases and atherosclerotic diseases have worse prognoses. Fourth, it is unclear which factors contribute or to what extent specific factors contribute to the development of atherosclerotic diseases and the promotion of malignant diseases. Moreover, accumulating clinical evidence has shown that patients with malignancies, compared with those without malignancies, have a higher likelihood of embolism, such as pulmonary embolism or coronary embolism due to thrombus or tumor tissue/mass, which might partly explain why patients with malignancies have a higher risk of cardiovascular events after PCI. Fifth, we set the endpoint as the time when the first event occurred and many were revascularizations. Revascularization is often resulted from routine follow-up coronary angiography and may not be clinically driven. Therefore, the possibility that many more clinically relevant outcomes are being missed cannot be denied. Finally, we did not set a control group (the history of malignancy only group). Thus, it is difficult to conclude the role of malignancy itself in future cardiovascular events. Therefore, further pathophysiological and molecular physiological studies, including animal experiments, are warranted. Additional detailed, prospective, large-scale, long-term surveillance may be needed to verify our theories.

6. Conclusion

Despite the limitations mentioned above, the results of this study demonstrate the following: patients with malignancies have significantly higher rates of adverse cardiovascular events but might not have the conventional prognostic factors, possibly due to the mechanism underlying the “obesity paradox.”

Acknowledgments

The authors thank all of the study collaborators for their devoted retrospective clinical records observations. The authors also thank all the paramedical staff and clinical secretaries for their kind support during this work.

Author contributions

SI has received honoraria from Daiichi Sankyo Co, Ltd, and has received grants from Astellas Pharma Inc; Bayer Yakuhin Ltd; Nippon Boehringer Ingelheim Co, Ltd; Boston Scientific Japan K. K.; Daiichi Sankyo Co, Ltd; Eisai Co, Ltd; MSD K.K.; Bristol-Myers Squibb K.K.; Actelion Pharmaceuticals Japan Ltd; Takeda Pharmaceuticals Japan Ltd; Teijin Pharma Ltd; Japan Lifeline Co; Ltd; Takeda Pharmaceutical Co, Ltd; Medtronic Japan Co Ltd; and Mitsubishi Tanabe Pharma. KO has received grants from Astellas Pharma Inc; Boston Scientific Japan K.K.; Mitsubishi Tanabe Pharma; and MSD K.K. SF has received grants from Ono Pharmaceutical Co, Ltd; Merck Sharp & Dohme Co, Ltd; Bristol-Myers Squibb, Chugai Pharmaceutical Co, Ltd; Novartis Pharma K.K. and Ltd; and Maruho Co, Ltd. NY belongs to departments supported by Chugai Pharmaceutical Co, Ltd and Yakuruto Honsya Co, Ltd. TK has received honoraria from Astellas Pharma Inc and Takeda Pharmaceutical Co, Ltd, and has received grants from Kyowa Hakko Kirin Co, Ltd; Eisai Co, Ltd; Astellas Pharma Inc; Taiho Pharmaceutical Co, Ltd; Takeda Pharmaceutical Co, Ltd; Nippon Kayaku Co, Ltd; Ono Pharmaceutical Co, Ltd; Sanofi K.K.; Pfizer Japan, Inc; Asahi Kasei Pharma Corporation. EA received grants from Astellas Pharma; AstraZeneca, Daiichi Sankyo; Kowa Pharmaceutical; Mitsubishi Tanabe Pharma; Ono Pharmaceutical; Pfizer Japan; Nippon Boehringer Ingelheim; Novartis Pharma; Novo Nordisk Pharma; Sanofi; Taisho Toyama Pharmaceutical; and Takeda Pharmaceutical and personal fees from Astellas Pharma; AstraZeneca; Daiichi Sankyo; Eli Lilly; Kowa Pharmaceutical; Mitsubishi Tanabe Pharma; MSD; Nippon Boehringer Ingelheim; Novartis Pharma; Novo Nordisk Pharma; Ono Pharmaceutical; Sanofi; Taisho Toyama Pharmaceutical; and Takeda Pharmaceutical. HII has received honoraria from AstraZeneca K.K.; Chugai-Roche Co, Ltd; and Takeda Pharmaceutical Co, Ltd, and has received grants from AstraZeneca K.K.; Chugai-Roche Co, Ltd; Daiichi Sankyo Co, Ltd; Eisai Co, Ltd; Kowa Pharmaceutical Co, Ltd, and Pfizer Japan, Inc. YK has received honoraria from Amgen Astellas BioPharma K.K.; AstraZeneca; Bristol-Myers Squibb; Daiichi
Sankyo Co, Ltd; Boehringer Ingelheim Japan; and Sanofi K.K. and has received grants from Abbott Vascular Japan; Astellas Pharma Inc; Boehringer Ingelheim Japan; Boston Scientific Japan K.K.; Daiichi Sankyo Co, Ltd; Japan Lifeline; Medtronic; Nitto; Osaka Pharmaceutical; Pfizer Japan, Inc; Sanofi K.K.; Sumitomo Dainippon Pharma; Takeda Pharmaceutical Co, Ltd; and Terumo. TM discloses lecture fees from Amgen Astellas BioPharma K.K.; Sanofi K.K.; Nitto Boehringer Ingelheim, Co, Ltd; Mitsubishi Tanabe Pharma Corporation; MSD; Bayer Yakuinu Ltd; Daiichi Sankyo Co, Ltd; and Takeda Pharmaceutical Co, Ltd, as well as research funds from Boehringer Ingelheim, Co, Ltd; Mitsubishi Tanabe Pharma Corporation; Astellas Pharma Inc; Daiichi Sankyo Co, Ltd; Pfizer Japan Inc; Bayer Yakuinu Ltd; Takeda Pharmaceutical Co, Ltd; Bristol-Myers Squibb; Novartis Pharma K.K.; and AstraZeneca K.K. MY has received honoraria from Daiichi Sankyo Co, Ltd and Sanofi K.K. KM has received honoraria from Daiichi Sankyo Co, Ltd; MSD K.K.; Nitto Boehringer Ingelheim Co, Ltd; and Actelion Pharmaceuticals Japan Ltd and has grants from Astellas Pharma Inc; Bayer Yakuinu Ltd; Nitto Boehringer Ingelheim Co, Ltd; Boston Scientific Japan K.K.; Daiichi Sankyo Co, Ltd; Eisai Co, Ltd; MSD K.K.; Bristol-Myers Squibb K.K.; Actelion Pharmaceuticals Japan Ltd; Teijin Pharma Ltd; Japan Lifeline Co, Ltd; Takeda Pharmaceutical Co, Ltd; Medtronic Japan Co, Ltd; and Mitsubishi Tanabe Pharma. HB has received honoraria from Eli Lilly Japan K.K. and Ono Pharmaceutical Co, Ltd and has received grants from Chugai Pharmaceutical Co, Ltd; Coviiden Japan Inc; Eli Lilly Japan K.K.; Shinogi & Co, & Co; Toyama Chemical Co, Ltd; Taiho Pharmaceutical Co, Ltd; Yakult Honsha Co, Ltd; Takeda Pharmaceutical Co, Ltd; Shin Nippon Biomedical Laboratories, Ltd; Merck Serono Co, Ltd; Novartis Pharma K.K.; and Johnson & Johnson K.K. KT has received honoraria from Amgen Astellas BioPharma K.K.; Bayer Yakuinu, Ltd; Daiichi Sankyo Co, Ltd; MSD K.K.; and Sanofi K.K. and has received grants from AstraZeneca K.K.; Astellas Pharma Inc; Bayer Yakuinu, Ltd; Boehringer Ingelheim Japan; Boston Scientific Japan K.K.; Chugai Pharmaceutical Co, Ltd; Daiichi Sankyo Co, Ltd; Eisai Co, Ltd; Kowa Pharmaceutical Co, Ltd; Mitsubishi Tanabe Pharma; MSD K.K.; Pfizer Japan Inc; Sanofi K.K.; Shinogi & Co, & Co; and Takeda Pharmaceutical Co, Ltd. The remaining authors have nothing to disclose.

Conceptualization: Daisuke Sueta, Noriaki Tabata.

Data curation: Daisuke Sueta, Noriaki Tabata, Satoshi Ikeda, Yuichi Saito, Kazuyuki Ozaki, Kenji Sakata, Takeshi Matsumura, Mutsumaru Yamamoto-Ibusuki, Yoji Murakami, Takayuki Jodai, Satoshi Fukushima, Naoya Yoshida.

Formal analysis: Daisuke Sueta, Noriaki Tabata.

Investigation: Daisuke Sueta, Noriaki Tabata, Tomomi Kamba, Eiichi Araki, Hirotaka Iwase, Kazuhiko Fuji, Hiroinobu Ihn, Yoshio Kobayashi, Tohru Minamino, Masakazu Yamagishi, Koji Maemura, Hideo Baba.

Methodology: Daisuke Sueta.

Project administration: Daisuke Sueta, Kenichi Tsujita.

Resources: Daisuke Sueta.

Software: Daisuke Sueta, Noriaki Tabata.

Supervision: Hideo Baba, Kenichi Tsujita.

Validation: Noriaki Tabata, Kunihiko Matsui, Kenichi Tsujita.

Visualization: Daisuke Sueta, Noriaki Tabata, Kunihiko Matsui.

Writing – original draft: Daisuke Sueta.

Writing – review and editing: Kenichi Tsujita.

References

[1] Hong RA, Imura T, Sumida KN, et al. Cardio-oncology/onsco-cardiology. Clin Cardiol 2010;33:733–7.

[2] Yeh ET. Onco-cardiology: the time has come. Texas Heart Inst J 2011;38:246–7.

[3] Sueta D, Hokimoto S. Onco-cardiology: present and future. Int J Cardiol 2016;215:38–40.

[4] Oeffinger KC, Mertens AC, Sklar CA, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006;355:1572–82.

[5] Parnass JL, Byers T, DiGuglielmo G, et al. Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study. Breast Cancer Res 2011;13:R64.

[6] Abdel-Qadir H, Austin PC, Lee DS, et al. A population-based study of cardiovascular mortality following early-stage breast cancer. JAMA Cardiol 2017;2:88–93.

[7] Hanrahan EO, Gonzalez-Angulo AM, Giordano SH, et al. Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma. J Clin Oncol 2007;25:4952–60.

[8] Velders MA, Boden H, Hofma SH, et al. Outcome after ST elevation myocardial infarction in patients with cancer treated with primary percutaneous coronary intervention. Am J Cardiol 2013;112:1867–72.

[9] Edwards BK, Noone AM, Mariotto AB, et al. Annual report to the nation on the status of cancer, 1975–2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer 2014;120:1290–314.

[10] Hess CN, Roe MT, Clare RM, et al. Relationship between cancer and cardiovascular outcomes following percutaneous coronary intervention. J Am Heart Assoc. 2015;4:e001779.

[11] Navi BB, Reiner AS, Kamel H, et al. Risk of arterial thromboembolism in patients with cancer. J Am Coll Cardiol 2017;70:926–38.

[12] Tabata N, Sueta D, Yamamoto E, et al. Outcome of current and history of cancer on the risk of cardiovascular events following percutaneous coronary intervention: a Kumamoto University Malignancy and Atherosclerosis (KUMA) study. Eur Heart J Qual Care Clin Outcomes 2018;4:290–300.

[13] Potts JE, Iliescu CA, Lopez Matas JC, et al. Percutaneous coronary intervention in cancer patients: a report of the prevalence and outcomes in the United States. Eur Heart J 2018;40:1790–1800.

[14] Armstrong GT, Oeffinger KC, Chen Y, et al. Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. J Clin Oncol 2013;31:3673–80.

[15] Armstrong GT, Kawashima T, Lessenring W, et al. Aging and risk of severe, disabling, life-threatening, and fatal events in the childhood cancer survivor study. J Clin Oncol 2014;32:1218–27.

[16] Malmberg M, Christiansen CB, Schmiegelow MD, et al. Incidence of new onset cancer in patients with a myocardial infarction - a nationwide cohort study. BMC Cardiovasc Disord 2018;18:198.

[17] Hasin T, Gerber Y, McNamll SM, et al. Patients with heart failure have an increased risk of incident cancer. J Am Coll Cardiol 2013;62:381–6.

[18] Hershman DL, Till C, Shen S, et al. Association of cardiovascular risk factors with cardiac events and survival outcomes among patients with breast cancer enrolled in SWOG clinical trials. J Clin Oncol 2018;36:2710–7.

[19] Okura Y, Takayama T, Ozaki K, et al. Burden of cardiovascular disease in Japanese cancer patients and survivors: a single cancer-center study in Niigata City. Int J Clin Oncol 2018;24:196–210.

[20] Sueta D, Hokimoto S, Usunomoya D, et al. New aspects of onco-cardiology. Int J Cardiol 2016;206:69–73.

[21] Sueta D, Tabata N, Akasaka T, et al. The dawn of a new era in onco-cardiology: the Kumamoto Classification. Int J Cardiol 2016;220:837–41.

[22] Sueta D, Tabata N, Yamashita T, et al. Letter to editor: management and research in cancer treatment-related cardiovascular toxicity: challenges and perspective. Int J Cardiol 2017;239:28.

[23] Liu YY, Agha AM, Lopez-Mattei J, et al. Interventional cardio-oncology: adding a new dimension to the cardio-oncology field. Front Cardiovasc Med 2018;5:48.

[24] Handy CE, Quisp S, Pinto X, et al. Synergistic opportunities in the interplay between cancer screening and cardiovascular disease risk assessment: together we are stronger. Circulation 2018;138:727–34.

[25] Tabata N, Sueta D, Yamamoto E, et al. A retrospective study of arterial stiffness and subsequent clinical outcomes in cancer patients undergoing percutaneous coronary intervention. J Hypertens 2019;37:754–64.
[26] Rabkin SW, Mathewson FA, Hsu PH. Relation of body weight to development of ischemic heart disease in a cohort of young North American men after a 26 year observation period: the Manitoba Study. Am J Cardiol 1977;39:452–8.

[27] Garrison RJ, Castelli WP. Weight and thirty-year mortality of men in the Framingham Study. Ann Intern Med 1985;103:1006–9.

[28] Groberg L, Weissman NJ, Waksman R, et al. The impact of obesity on the short-term and long-term outcomes after percutaneous coronary intervention: the obesity paradox? J Am Coll Cardiol 2002;39:378–84.

[29] Romero-Corral A, Montori VM, Somers VK, et al. Association of overweight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies. Lancet 2006;368:666–78.

[30] Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol 2009;53:1925–32.

[31] Carnethon MR, De Chavez PJ, Biggs ML, et al. Association of weight status with mortality in adults with incident diabetes. JAMA 2012;308:581–90.

[32] Stovitz SD, Banack HR, Kaufman JS. Structural bias in studies of cardiovascular disease: let’s not be fooled by the “obesity paradox”. Can J Cardiol 2018;34:540–2.

[33] Neumann FJ, Sousa-Uva M, Aithloon A, et al. 2018 ESC/EACTS guidelines on myocardial revascularization. Eur J Heart J 2019;40:87–165.

[34] Nishihara T, Tokitsu T, Sueta D, et al. Serum potassium and cardiovascular events in heart failure with preserved left ventricular ejection fraction patients. Am J Hypertens 2018;31:1098–103.

[35] National Kidney F. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(2 Suppl 1):S1–266.

[36] Thygesen K, Alpert JS, Jaffe AS, et al. Fourth universal definition of myocardial infarction (2018). J Am Coll Cardiol 2018;72:2231–64.

[37] Austen WG, Edwards JE, Frye RL, et al. A reporting system on patients evaluated for coronary artery disease. Report of the ad hoc committee for grading of coronary artery disease. Council on Cardiovascular Surgery, American Heart Association. Circulation 1975;51(4 Suppl):3–40.

[38] Sueta D, Suyama K, Sueta A, et al. Lenvatinib, an oral multi-kinases inhibitor, associated hypertension: potential role of vascular endothelial dysfunction. Atherosclerosis 2017;260:116–20.

[39] Tomita Y, Sueta D, Kakiuchi Y, et al. Acute coronary syndrome as a possible immune-related adverse event in a lung cancer patient achieving a complete response to anti-PD-1 immune checkpoint antibody. Ann Oncol 2017;28:2893–5.

[40] OECD Indicators. Co-operation Of E, Development. Health at a Glance 2015. Paris: OECD Publishing; 2015.

[41] Habib A, Lakkins NM, Dokainish H. The obesity paradox: fact or fiction? Am J Cardiol 2006;98:944–8.

[42] Coutinho T, Goel K, Correa de Sa D, et al. Central obesity and survival in subjects with coronary artery disease: a systematic review of the literature and collaborative analysis with individual subject data. J Am Coll Cardiol 2011;57:1877–86.

[43] Tsugane S, Gey F, Ichinowatari Y, et al. Cross-sectional epidemiologic study for assessing cancer risks at the population level I. Study design and participation rate. J Epidemiol 1992;2:75–81.

[44] Tsugane S, Sasazuki S, Koyabashi M, et al. Salt and salted food intake and subsequent risk of gastric cancer among middle-aged Japanese men and women. Br J Cancer 2004;90:128–34.

[45] Bowers K, Albanes D, Limburg P, et al. A prospective study of anthropometric and clinical measurements associated with insulin resistance syndrome and colorectal cancer in male smokers. Am J Epidemiol 2006;164:652–64.

[46] Ahmed RL, Schmitz KH, Anderson KE, et al. The metabolic syndrome and risk of incident colorectal cancer. Cancer 2006;107:28–36.

[47] Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? The lancet 2001;357:539–45.

[48] Cozzen DM, Werb Z. Inflammation and cancer. Nature 2002;420:860–7.

[49] Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140:833–99.

[50] Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105:1133–43.

[51] Libby P, Okamoto Y, Rocha VZ, et al. Inflammation in atherosclerosis. Circ. J 2010;74:213–20.

[52] Libby P. Inflammation in atherosclerosis. Arterioscler Thromb Vasc Biol 2012;32:2045–51.

[53] Roshani R, McCarthy F, Hagemann T. Inflammatory cytokines in human pancreatic cancer. Cancer Lett 2014;345:157–63.

[54] Kore RA, Abraham EC. Inflammatory cytokines, interleukin-1 beta and tumor necrosis factor-alpha, upregulated in glioblastoma multiforme, raise the levels of CRYAB in exosomes secreted by U373 glioma cells. Biochem Biophys Res Commun 2014;453:266–71.

[55] Yasmin R, Siraj S, Hassan A, et al. Epigenetic regulation of inflammatory cytokines and associated genes in human malignancies. Mediators Inflamm 2015;2015:207103.

[56] Steensma DP, Bejar R, Jaiswal S, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood 2015;126:9–16.

[57] Libby P, Ebert BL. CHIP (clonal hematopoiesis of indeterminate potential) potent and newly recognized contributor to cardiovascular risk. Circulation 2018;138:666–8.

[58] Shuomi H, Morimoto T, Kitaguchi S, et al. The ReACT trial: randomized evaluation of routine follow-up coronary angiography after percutaneous coronary intervention trial. JACC Cardiovasc Interv 2017;10:109–17.

[59] Jaworski C, Mariani JA, Wheeler G, et al. Cardiac complications of thoracic irradiation. J Am Coll Cardiol 2013;61:2319–28.